Triple Burden: The Incorrigible Threat of Tuberculosis, HIV, and COVID-19


Cite item

Full Text

Abstract

The Coronavirus-19 (COVID-19) hasn’t seen the dawn since its emergence, however waxing and waning has resulted in the emergence of deadly variants. The effects of pandemic have not been limited to its virulence, but have rather conferred multiple collateral effects, especially in developing countries; thereby, designating it as a SYNDEMIC. The same culminated in neglect of non-COVID-19 conditions like tuberculosis (TB) and human immunodeficiency virus-acquired immunodeficiency syndrome (HIV/AIDS). Besides being the prognostic factor for severe COVID-19, these infections in hidden pockets served as reservoir for emergence of the deadly Omicron. Another significant impact of this juxtaposition was on the delivery of healthcare services for TB and HIV.

2:The unanticipated COVID-19 pandemic turned the path of ongoing progress of elimination programs. Direct consequences of the COVID-19 pandemic were pronounced on diagnosis, treatment, and services for patients with TB and HIV. Essential TB services were reallocated to the COVID-19 rapid response task force. However, despite escalating the tribulations, this triple burden has simultaneously taught lessons to escalate the progress of halted programs. The pandemic has catalyzed an unusual level of collaboration among scientists, which can be exploited for TB and HIV. Fast-track diagnostics, digitalization, contact tracing, and vaccine development have enabled world to envision the same for TB/HIV.

About the authors

Parakriti Gupta

Department of Microbiology, Government Medical College and Hospital

Email: info@benthamscience.net

Diljot Sandhu

Department of Microbiology, Government Medical College and Hospital

Email: info@benthamscience.net

Varsha Gupta

Department of Microbiology, GMCH

Email: info@benthamscience.net

Lipika Singhal

Department of Microbiology, Government Medical College and Hospital

Author for correspondence.
Email: info@benthamscience.net

References

  1. WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Available from: https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china
  2. Tracking SARS-CoV-2 variants. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants
  3. Courtin E, Vineis P. COVID-19 as a syndemic. Front Public Health 2021; 9763830. doi: 10.3389/fpubh.2021.763830 PMID: 34568273
  4. Piketty J, Carbonnel M, Murtada R, et al. Collateral damage of COVID-19 pandemic: The impact on a gynecologic surgery department. J Gynecol Obstet Hum Reprod 2022; 51(1): 102255. doi: 10.1016/j.jogoh.2021.102255 PMID: 34757223
  5. Thiagarajan K. Covid-19 exposes the high cost of India’s reliance on private healthcare. BMJ 2020; 370: m3506. doi: 10.1136/bmj.m3506 PMID: 32912849
  6. Tamuzi JL, Ayele BT, Shumba CS, et al. Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC Infect Dis 2020; 20(1): 744. doi: 10.1186/s12879-020-05450-4 PMID: 33036570
  7. The Connection between TB and HIV ⋅ Pamphlets, Brochures, Booklets⋅Publications & Products ⋅ TB ⋅ CDC. 2022. Available from: https://www.cdc.gov/tb/publications/pamphlets/tbandhiv_eng.htm
  8. Waters R, Ndengane M, Abrahams MR, Diedrich CR, Wilkinson RJ, Coussens AK. The Mtb -HIV syndemic interaction: Why treating M. tuberculosis infection may be crucial for HIV-1 eradication. Future Virol 2020; 15(2): 101-26. doi: 10.2217/fvl-2019-0069 PMID: 32273900
  9. Ssentongo P, Ssentongo AE, Heilbrunn ES, Du P. 393. Prevalence of HIV in patients hospitalized for COVID-19 and associated mortality outcomes: A systematic review and meta-analysis. Open Forum Infect Dis 2020; 7(S1): S266. doi: 10.1093/ofid/ofaa439.588
  10. Nachega JB, Kapata N, Sam-Agudu NA, et al. Minimizing the impact of the triple burden of COVID-19, tuberculosis and HIV on health services in sub-Saharan Africa. Int J Infect Dis 2021; 113(S1): S16-21. doi: 10.1016/j.ijid.2021.03.038 PMID: 33757874
  11. Karim SSA, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 2009; 374(9693): 921-33. doi: 10.1016/S0140-6736(09)60916-8 PMID: 19709731
  12. Khandia R, Singhal S, Alqahtani T, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res 2022; 209112816. doi: 10.1016/j.envres.2022.112816 PMID: 35093310
  13. Freer J, Mudaly V. HIV and covid-19 in South Africa BMJ 2022; 376e069807 doi: 10.1136/bmj-2021-069807 PMID: 35086921
  14. Brumme ZL, Mwimanzi F, Lapointe HR, et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. medRxiv 2021; 2021.10.03.21264320. doi: 10.1101/2021.10.03.21264320
  15. Coronavirus disease (COVID-19) and people living with HIV. Available from:. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-covid-19-and-people-living-with-hiv
  16. Logunov DY, Livermore DM, Ornelles DA, et al. COVID-19 vaccination and HIV-1 acquisition. Lancet 2022; 399(10333): e34-5. doi: 10.1016/S0140-6736(22)00332-4 PMID: 35397866
  17. Chun HM, Milligan K, Agyemang E, et al. A systematic review of COVID-19 vaccine antibody responses in people with HIV. Open Forum Infect Dis 2022; 9(11): ofac579. doi: 10.1093/ofid/ofac579 PMID: 36438620
  18. Hassold N, Brichler S, Ouedraogo E, et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. AIDS 2022; 36(4): F1-5. doi: 10.1097/QAD.0000000000003166 PMID: 35013085
  19. Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. Lancet Glob Health 2020; 8(9): e1132-41. doi: 10.1016/S2214-109X(20)30288-6 PMID: 32673577
  20. Global Fund Results Report Reveals COVID-19 Devastating Impact on HIV, TB and Malaria Programs. Available from: https://www.theglobalfund.org/en/news/2021/2021-09-08-global-fund-results-report-reveals-covid-19-devastating-impact-on-hiv-tb-and-malaria-programs/
  21. Can Sarınoğllu R, Sili U, Eryuksel E, Olgun Yildizeli S, Cimsit C, Karahasan Yagci A. Tuberculosis and COVID-19: An overlapping situation during pandemic. J Infect Dev Ctries 2020; 14(7): 721-5. doi: 10.3855/jidc.13152 PMID: 32794460
  22. Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic. Available from: https://www.who.int/news/item/14-10-2021-tuberculosis-deaths-rise-for-the-first-time-in-more-than-a-decade-due-to-the-covid-19-pandemic
  23. On World TB day WHO calls for increased investments into TB services and research. Available from: https://www.who.int/news/item/21-03-2022-on-world-tb-day-who-calls-for-increased-investments-into-tb-services-and-research
  24. Perween R. PraveenKumar M, Shrivastava T, et al. The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41. Int Immunopharmacol 2021; 101(Pt B): 108187. doi: 10.1016/j.intimp.2021.108187 PMID: 34649114
  25. Silver ZA, Antonopoulos A, Haslam SM, et al. Discovery of o-linked carbohydrate on HIV-1 envelope and its role in shielding against one category of broadly neutralizing antibodies. Cell Rep 2020; 30(6): 1862-1869.e4. doi: 10.1016/j.celrep.2020.01.056 PMID: 32049016
  26. Mishra N, Kumar S, Singh S, et al. Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma. PLoS Pathog 2021; 17(9): e1009958. doi: 10.1371/journal.ppat.1009958 PMID: 34559854
  27. Global tuberculosis report 2020. Available from:. https://www.who.int/publications-detail-redirect/9789240013131
  28. CDC announces Think. Test. Treat TB: a campaign to raise awareness of latent TB infection ⋅ Dear Colleague Letters ⋅ TB ⋅ CDC. Available from: https://www.cdc.gov/tb/publications/letters/2022/tb-campaign.html
  29. TB & COVID-19. Available from:. https://www.who.int/teams/global-tuberculosis-programme/covid-19
  30. Mousquer GT, Peres A, Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace. Tuberculosis 2021; 126102020. doi: 10.1016/j.tube.2020.102020 PMID: 33246269
  31. The End TB Strategy. Available from:. https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy
  32. States and UTs accelerate action to end TB by 2025. Available from:. https://www.who.int/india/news/detail/09-11-2021-states-and-uts-accelerate-action-to-end-tb-by-2025
  33. Cilloni L, Fu H, Vesga JF, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine 2020; 28100603. doi: 10.1016/j.eclinm.2020.100603 PMID: 33134905
  34. WHO Global TB progress at risk Available from: https://www.who.int/news/item/14-10-2020-who-global-tb-progress-at-risk
  35. End TB. The clock is ticking ⋅ World Economic Forum. Available from:. https://www.weforum.org/agenda/2021/03/end-tb-the-clock-is-ticking/
  36. Shrinivasan R, Rane S, Pai M. India’s syndemic of tuberculosis and COVID-19. BMJ Glob Health 2020; 5(11): e003979. doi: 10.1136/bmjgh-2020-003979 PMID: 33199280
  37. Tuberculosis and COVID-19 ⋅ Stop TB Partnership. Available from: . https://www.stoptb.org/covid19
  38. The impact of COVID-19 on HIV, TB and malaria services and systems for health - Updates - The Global Fund to Fight AIDS, Tuberculosis and Malaria. Available from: https://www.theglobalfund.org/en/updates/2021/2021-04-13-the-impact-of-covid-19-on-hiv-tb-and-malaria-services-and-systems-for-health/
  39. HMIS-Health Management Information System. Available from:. https://hmis.nhp.gov.in/#!/aboutus
  40. Chatterjee P. Is India missing COVID-19 deaths? Lancet 2020; 396(10252): 657. doi: 10.1016/S0140-6736(20)31857-2 PMID: 32891197
  41. Unite To Fight. Available from:. https://www.theglobalfund.org/en/unite-to-fight/
  42. Directives regarding TB services during Covid19 emergency period :: Central TB Division. Available from: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=5428&lid=3509
  43. Pai M. Tuberculosis And Covid-19: Fighting A Deadly Syndemic. Forbes. Available from: https://www.forbes.com/sites/madhukarpai/2020/09/26/tuberculosis-and-covid-19-fighting-a-deadly-syndemic/
  44. How Covid is making it tougher to tackle TB, AIDS, malaria and child health. Available from: https://theprint.in/health/how-covid-is-making-it-tougher-to-tackle-tb-aids-malaria-and-child-health/443658/
  45. Technical guidance. Available from: https://www.who.int/india/home/emergencies/ongoing-disease-outbreak-disasters/technical-guidance
  46. Coronavirus disease (COVID-19): HIV and antiretrovirals. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-hiv-and-antiretrovirals
  47. An S, Li Y, Lin Y, et al. Genome-wide profiling reveals alternative polyadenylation of innate immune-related mRNA in patients with COVID-19. Front Immunol 2021; 12756288. doi: 10.3389/fimmu.2021.756288 PMID: 34777369
  48. Chen Y, Wang G, Li J, et al. CASA: A comprehensive database resource for the COVID-19 Alternative splicing atlas. J Transl Med 2022; 20(1): 473. doi: 10.1186/s12967-022-03699-8 PMID: 36266726
  49. An S, Xie Z, Liao Y, et al. Systematic analysis of clinical relevance and molecular characterization of m6A in COVID-19 patients. Genes Dis 2022; 9(5): 1170-3. doi: 10.1016/j.gendis.2021.12.005 PMID: 35013711
  50. Joy M, Malavika B, Asirvatham ES, Sudarsanam TD, Jeyaseelan L. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries. Clin Epidemiol Glob Health 2021; 9: 202-3. doi: 10.1016/j.cegh.2020.08.015 PMID: 33163696
  51. Gong W, Mao Y, Li Y, Qi Y. BCG vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents. Int Immunopharmacol 2022; 108108870. doi: 10.1016/j.intimp.2022.108870 PMID: 35597119
  52. Glynn JR, Dube A, Fielding K, Crampin AC, Kanjala C, Fine PEM. The effect of BCG revaccination on all-cause mortality beyond infancy: 30-year follow-up of a population-based, double-blind, randomised placebo-controlled trial in Malawi. Lancet Infect Dis 2021; (21)11: 1590-7. doi: 10.1016/S1473-3099(20)30994-4 PMID: 34237262
  53. COVID-19 Strategic Preparedness and Response Plan Operational Planning Guideline. Available from: https://www.who.int/publications/m/item/covid-19-strategicpreparedness-and-response-plan-operational-planning-guideline

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers